Search Menu

IAS 13th Kigali 2025

IAS 2025: Limited access to CD4 tests misses late diagnoses and advanced HIV disease (AHD)

IAS 2025: Induced stress can increase HIV dynamics

Featured IAS 2025: WHO major updates on injectables, AHD, breastfeeding, infant prophylaxis and peer support

13th IAS Conference on HIV Science (IAS 2025): Introduction and early reports

IAS 2025: The Kigali Manifesto on the inclusion of people living with HIV in clinical research

IAS 2025: Switching to injectable CAB/RPV-LA with detectable viral load: results from the OPERA cohort

IAS 2025: Switching to dual ART after durable suppression on triple-drug ART in West and Central Africa

IAS 2025: Increases in reports of HIV criminalisation cases globally

IAS 2025: Once-weekly oral ART with ulonivirine plus islatravir: 24-week phase 2 results

IAS 2025: Reduced dosing could be a safe option for adults: crisis response to ART stock-outs

IAS 2025: 5-on 2-off dosing is inferior to continuous ART in BREATHER Plus – but no differences in clinical outcomes

IAS 2025: Long-acting CAB/RPV in people with suboptimal adherence: IMPALA study results at 48 weeks

IAS 2025: Once-monthly oral PrEP using MK-8527: the drug that could stop HIV

IAS 2025: “We will not be erased” – a community Call to Action

IAS 2025: HIV care is political: early focus on the funding crisis

IAS 2025: HIV cure research at IAS 2025

IAS 2025: Kigali Call to Action: sign-on to global leaders